UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 1	LO-Q
--------	------

☑ QUARTERLY REPORT PURSI	UANT TO SECTION 1	13 OR 15(d) OF THE SEC	URITIES EXCHANGE ACT OF 1934	
For the Quarterly Period Ended Marc	h 31, 2023			
		OR		
☐ TRANSITION REPORT PURSI	UANT TO SECTION 1	L3 OR 15(d) OF THE SEC	URITIES EXCHANGE ACT OF 1934	
For the Transition Period From	to			
For the Hansiton Fenou From		ssion File Number 001-37	845	
N/I		FT CORPO		
IVI	ICRUSU	FI CORPC	RATION	
WASHINGT (STATE OF INCORF			91-1144442 (I.R.S. ID)	
(STATE OF INCOM	ONE MICROSOFT V	NAY, REDMOND, WASHINGTO (425) 882-8080 ww.microsoft.com/investor	, ,	
Securities registered pursuant to Section 12((b) of the Act:			
Title of each class		Trading Symbol	Name of exchange on which registered	
Common stock, \$0.00000625 par value pe 3.125% Notes due 2028 2.625% Notes due 2033	r share	MSFT MSFT MSFT	NASDAQ NASDAQ NASDAQ	
Indicate by check mark whether the registra preceding 12 months (or for such shorter per 90 days. Yes ⊠ No □	nt (1) has filed all reports riod that the registrant wa	s required to be filed by Sections required to file such reports),	n 13 or 15(d) of the Securities Exchange Act of 1934 du and (2) has been subject to such filing requirements for t	ring the
			required to be submitted pursuant to Rule 405 of Regula ant was required to submit such files). Yes $\ oxdot$ No $\ \Box$	tion S-
			n-accelerated filer, a smaller reporting company, or an el company," and "emerging growth company" in Rule 12b-	
Large Accelerated Filer ⊠ Non-accelerated Filer □			Accelerated Filer □ Smaller Reporting Company □ Emerging Growth Company □	
If an emerging growth company, indicate by financial accounting standards provided purs	3		extended transition period for complying with any new or	revise
Indicate by check mark whether the registrar	nt is a shell company (as c	defined in Rule 12b-2 of the Exc	change Act). Yes □ No ⊠	
Indicate the number of shares outstanding of	each of the issuer's class	ses of common stock, as of the	latest practicable date.	
Class			Outstanding as of April 20,	2023
Common Stock, \$0.00000625 par value per	share		7,435,487,575 sh	ıares
	share			-

As of March 31, 2023, we have additional operating and finance leases, primarily for datacenters, that have not yet commenced of \$5.0 billion and \$21.9 billion, respectively. These operating and finance leases will commence between fiscal year 2023 and fiscal year 2030 with lease terms of 1 year to 18 years.

NOTE 14 — CONTINGENCIES

U.S. Cell Phone Litigation

Microsoft Mobile Oy, a subsidiary of Microsoft, along with other handset manufacturers and network operators, is a defendant in 46 lawsuits, including 45 lawsuits filed in the Superior Court for the District of Columbia by individual plaintiffs who allege that radio emissions from cellular handsets caused their brain tumors and other adverse health effects. We assumed responsibility for these claims in our agreement to acquire Nokia's Devices and Services business and have been substituted for the Nokia defendants. Nine of these cases were filed in 2002 and are consolidated for certain pre-trial proceedings; the remaining cases are stayed. In a separate 2009 decision, the Court of Appeals for the District of Columbia held that adverse health effect claims arising from the use of cellular handsets that operate within the U.S. Federal Communications Commission radio frequency emission guidelines ("FCC Guidelines") are pre-empted by federal law. The plaintiffs allege that their handsets either operated outside the FCC Guidelines or were manufactured before the FCC Guidelines went into effect. The lawsuits also allege an industry-wide conspiracy to manipulate the science and testing around emission guidelines.

In 2013, the defendants in the consolidated cases moved to exclude the plaintiffs' expert evidence of general causation on the basis of flawed scientific methodologies. In 2014, the trial court granted in part and denied in part the defendants' motion to exclude the plaintiffs' general causation experts. The defendants filed an interlocutory appeal to the District of Columbia Court of Appeals challenging the standard for evaluating expert scientific evidence. In October 2016, the Court of Appeals issued its decision adopting the standard advocated by the defendants and remanding the cases to the trial court for further proceedings under that standard. The plaintiffs have filed supplemental expert evidence, portions of which were stricken by the court. A hearing on general causation took place in September of 2022.

Other Contingencies

We also are subject to a variety of other claims and suits that arise from time to time in the ordinary course of our business. Although management currently believes that resolving claims against us, individually or in aggregate, will not have a material adverse impact in our consolidated financial statements, these matters are subject to inherent uncertainties and management's view of these matters may change in the future.

As of March 31, 2023, we accrued aggregate legal liabilities of \$177 million. While we intend to defend these matters vigorously, adverse outcomes that we estimate could reach approximately \$600 million in aggregate beyond recorded amounts are reasonably possible. Were unfavorable final outcomes to occur, there exists the possibility of a material adverse impact in our consolidated financial statements for the period in which the effects become reasonably estimable.

NOTE 15 — STOCKHOLDERS' EQUITY

Share Repurchases

On September 18, 2019, our Board of Directors approved a share repurchase program authorizing up to \$40.0 billion in share repurchases. This share repurchase program commenced in February 2020 and was completed in November 2021.

On September 14, 2021, our Board of Directors approved a share repurchase program authorizing up to \$60.0 billion in share repurchases. This share repurchase program commenced in November 2021, following completion of the program approved on September 18, 2019, has no expiration date, and may be terminated at any time. As of March 31, 2023, \$26.9 billion remained of this \$60.0 billion share repurchase program.